Sorrento Presents Preliminary Results of STI-2020 Against COVID-19
The approval follows the EMA’s CHMP positive opinion based on a study assessing Remsima SC (120 mg) vs IV formulations in patients with Crohn’s disease and ulcerative colitis, evaluating its PK, efficacy, and safety The study resulted in high efficacy and safety comparable with IV formulation and the SC administration will also reduce the treatment […]Read More